Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.60 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.60 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vamicamide SCHEMBL30700593 | 1.00 | KCNH2 (0.65) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL9393264 | 1.00 | KCNH2 (0.65) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL9393357 | 0.99 | KCNH2 (0.64) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Vamicamide SCHEMBL4603765 | 0.99 | KCNH2 (0.64) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Aminopentamide Sulfate SCHEMBL251458 | 0.85 | GRIN1 (0.75) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Aminopentamide Sulfate SCHEMBL203612 | 0.80 | GRIN1 (0.68) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL23931452 | 0.79 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| (S)-Disopyramide SCHEMBL41811 | 0.79 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL16153 | 0.79 | KCNH2 (1.00) | KCNH2OPRK1BLMSLC22A2SLC22A1 | |
| Disopyramide SCHEMBL546251 | 0.78 | KCNH2 (0.98) | KCNH2OPRK1BLMSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20100113469-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | claimed |
| EP-2141992-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | Merck & Co., Inc. (US) | 2010-01-13 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| WO-2008121268-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | MERCK & CO., INC. (US) | 2008-10-09 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007146224-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-20050025716-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | NOVADEL PHARMA, INC. | 2005-02-03 | — | — | US | claimed |
| WO-2004019910-A2 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING DISORDERS OF THE GASTROINTESTINAL TRACT OR URINARY TRACT | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20030095926-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | NOVADEL PHARMA INC. | 2003-05-22 | — | — | US | claimed |
| EP-1307184-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2003-05-07 | — | — | EP | claimed |
| WO-2002011707-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | claimed |
| US-5770221-A | HIGH AND LOW MOLECULAR WEIGHT POLYISOBUTYLENE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-06-23 | — | — | US | claimed |
| EP-0452809-B1 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-07-27 | — | — | EP | claimed |
| EP-0452809-A2 | A therapeutic agent for pollakiuria, urinary urgency or incontinence of urine comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113469-A1 | COMBINATION THERAPY FOR THE TREATMENT-OF LOWER URINARY TRACT SYMPTOMS | KLK5, ADRB1, ADRB3 | KCNH2 246/4885OPRK1 100/4885BLM 4303/4885 |
| US-20030203899-A1 | Drugs for incontinence | PDE3A, NOS1, PDE3B | KCNH2 2832/4885OPRK1 194/4885BLM 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.